January 27, 2014
Executive Serially Backed By Private Equity Firms Becomes CEO of Meridien Research
On January 27, 2014, Meridien Research appointed Tony Busa as its Chief Executive Officer. Tony has been the CEO or President of three successive private equity-backed companies in the clinical trial management and lab services arena. Prior to joining Meridien, Tony served as CEO of World Wide Clinical Trials, a Jordan Industries portfolio company, where he tripled revenues over three years. Tony was previously the President of DGD and Esoterix, a Behrman Capital portfolio company, where revenues more than doubled over 5 years to $140 million.